Grease: Observatory of the Breast cancer practices in France

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

En France, le cancer du sein est le cancer le plus fréquent chez les femmes, avec une incidence en 2023 de 61 214 cas et reste la première cause de décès par cancer chez les femmes, avec environ 12100 décès par cancer du sein en 2018.Il n’y a pas de mise à jour détaillée sur l’épidémiologie par sous-type. La prise en charge thérapeutique évolue significativement avec l’arrivée d’innovations telles que le tucatinib ou le déruxtécan de trastuzumab pour les patients HER2+ ou les immunothérapies pour les patients atteints de TNBC.

L'objectif principal de cette étude est d'évaluer l'épidémiologie (prévalence, incidence) du cancer du sein en France sur la période 2010-2023 et de décrire la prise en charge thérapeutique des patients atteints de cancer du sein et son évolution dans le temps

The secondary objectives are to:
1. Describe the natural history of the BC
2. Describe the disease evolution: overall survival (OS) over time
3. Assess the effectiveness of specific treatments through the analysis of overall survival (OS), time to next treatment (TNT) and proportion of long-term responders,
4. Assess the evolution of BC healthcare pathway, including hospitalization care pathways (hospital at-home, outpatient ambulatory, length of stay for conventional surgical hospitalization); supportive care treatments, oncogenetic visits.
5. Describe the healthcare resource use of BC (treatments, consultations of healthcare professionals, paramedical acts, medical procedures, laboratory tests, drugs, medical devices, medical transports, sick leaves)
6. Assess the persistence and the compliance of BC specific treatments distributed in pharmacies outside the hospital (oral, intramuscular and subcutaneous forms) in the adjuvant setting
7. Assess the correlation between Time to first-line (1L) therapy discontinuation in metastatic stage of BC and OS

Justification of the public interest: In the light of the new BC treatments available, this study will help to better understand healthcare management and update BC epidemiology. Furthermore, by describing the burden of the disease, results of this study could support the development of new treatments and the future discussions between Roche and the French National Authority for Health.

Methodologie
Database: ESND
Profondeur historique: 19 ans en plus de l’année en cours

Design: This is a retrospective observational study using secondary data from the ESND database related to all adult women with a marker of BC management in France.

Population d'étude:

A. For Incidence/prevalence analyses: all French women from the ESND with evidence of BC management (BC hospitalization or active LTD related to BC or BC specific drug dispensation) between 1 January 2010 and 31 December 2023

B. For all other analyses (including therapeutic management of BC patients and its evolution over time): all French women from the ESND treated for an incident BC between 1 January 2010 and 31 December 2022